ES2770733T3 - Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas - Google Patents
Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas Download PDFInfo
- Publication number
- ES2770733T3 ES2770733T3 ES15707019T ES15707019T ES2770733T3 ES 2770733 T3 ES2770733 T3 ES 2770733T3 ES 15707019 T ES15707019 T ES 15707019T ES 15707019 T ES15707019 T ES 15707019T ES 2770733 T3 ES2770733 T3 ES 2770733T3
- Authority
- ES
- Spain
- Prior art keywords
- weight
- acid
- percent
- nanoparticles
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939363P | 2014-02-13 | 2014-02-13 | |
| PCT/US2015/015887 WO2015123562A1 (en) | 2014-02-13 | 2015-02-13 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2770733T3 true ES2770733T3 (es) | 2020-07-02 |
Family
ID=52595474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15707019T Active ES2770733T3 (es) | 2014-02-13 | 2015-02-13 | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10080723B2 (https=) |
| EP (1) | EP3104838B1 (https=) |
| JP (1) | JP6573895B2 (https=) |
| CA (1) | CA2939261C (https=) |
| DK (1) | DK3104838T3 (https=) |
| ES (1) | ES2770733T3 (https=) |
| HU (1) | HUE047934T2 (https=) |
| PL (1) | PL3104838T3 (https=) |
| PT (1) | PT3104838T (https=) |
| SI (1) | SI3104838T1 (https=) |
| WO (1) | WO2015123562A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3104838T1 (sl) | 2014-02-13 | 2020-04-30 | Pfizer Inc. | Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev |
| JP6554493B2 (ja) | 2014-06-24 | 2019-07-31 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス |
| HK1256704A1 (zh) | 2015-08-21 | 2019-10-04 | 辉瑞公司 | 包含治疗剂的治疗性纳米粒及其制备和使用方法 |
| EP3432864B1 (en) * | 2016-03-22 | 2020-05-06 | Pfizer Inc | Process for preparing therapeutic nanoparticles |
| CA3060306A1 (en) | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| US12357582B2 (en) | 2017-11-03 | 2025-07-15 | The Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations |
| CN112236459A (zh) * | 2018-04-23 | 2021-01-15 | 灰色视觉公司 | 改善的连续微粒制造 |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| JP2025538488A (ja) * | 2022-11-18 | 2025-11-28 | ハイマ セラピューティクス，エルエルシー | ペプチド修飾されたリポソーム用凍結乾燥緩衝液 |
| TW202444365A (zh) | 2023-01-31 | 2024-11-16 | 漢達生技醫藥股份有限公司 | 改良之卡博替尼組合物及其使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869884B2 (en) * | 2002-08-22 | 2005-03-22 | Chartered Semiconductor Manufacturing Ltd. | Process to reduce substrate effects by forming channels under inductor devices and around analog blocks |
| WO2005009357A2 (en) | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| JP2012501965A (ja) * | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| MX356097B (es) * | 2012-09-17 | 2018-05-14 | Pfizer Inc Star | Proceso para la preparacion de nanoparticulas terapeuticas. |
| BR112015005878A2 (pt) | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
| ES2640648T3 (es) * | 2013-09-16 | 2017-11-03 | Astrazeneca Ab | Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso |
| SI3104838T1 (sl) | 2014-02-13 | 2020-04-30 | Pfizer Inc. | Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev |
| MA39734B1 (fr) * | 2014-03-14 | 2019-07-31 | Pfizer | Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation |
-
2015
- 2015-02-13 SI SI201531085T patent/SI3104838T1/sl unknown
- 2015-02-13 WO PCT/US2015/015887 patent/WO2015123562A1/en not_active Ceased
- 2015-02-13 EP EP15707019.4A patent/EP3104838B1/en active Active
- 2015-02-13 ES ES15707019T patent/ES2770733T3/es active Active
- 2015-02-13 DK DK15707019.4T patent/DK3104838T3/da active
- 2015-02-13 HU HUE15707019A patent/HUE047934T2/hu unknown
- 2015-02-13 PL PL15707019T patent/PL3104838T3/pl unknown
- 2015-02-13 CA CA2939261A patent/CA2939261C/en active Active
- 2015-02-13 PT PT157070194T patent/PT3104838T/pt unknown
- 2015-02-13 JP JP2016551767A patent/JP6573895B2/ja active Active
- 2015-02-13 US US15/118,737 patent/US10080723B2/en active Active
-
2018
- 2018-09-07 US US16/124,605 patent/US10583092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190111004A1 (en) | 2019-04-18 |
| JP2017505800A (ja) | 2017-02-23 |
| US10583092B2 (en) | 2020-03-10 |
| US20170042828A1 (en) | 2017-02-16 |
| CA2939261A1 (en) | 2015-08-20 |
| WO2015123562A1 (en) | 2015-08-20 |
| HUE047934T2 (hu) | 2020-05-28 |
| DK3104838T3 (da) | 2020-02-24 |
| EP3104838B1 (en) | 2020-01-01 |
| EP3104838A1 (en) | 2016-12-21 |
| SI3104838T1 (sl) | 2020-04-30 |
| US10080723B2 (en) | 2018-09-25 |
| PT3104838T (pt) | 2020-02-14 |
| CA2939261C (en) | 2023-03-28 |
| JP6573895B2 (ja) | 2019-09-11 |
| PL3104838T3 (pl) | 2020-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2770733T3 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas | |
| ES2732377T3 (es) | Procedimiento de preparación de nanopartículas terapéuticas | |
| ES2784423T3 (es) | Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso | |
| ES2834927T3 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas | |
| US20170119672A1 (en) | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods Of Making And Using Same | |
| ES2847894T3 (es) | Nanopartículas terapéuticas dirigidas y procedimientos de fabricación y uso de las mismas | |
| KR20180054855A (ko) | 치료제를 포함하는 치료 나노입자, 및 이를 제조 및 사용하는 방법 | |
| JP2017513950A (ja) | Ｋ−ｒａｓ変異を有するがんを処置するためのドセタキセルを含むナノ粒子 | |
| ES2872552T3 (es) | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas | |
| US20170151181A1 (en) | Methods of treating cancers with therapeutic nanoparticles | |
| ES2797302T3 (es) | Procedimiento para la preparación de nanopartículas terapéuticas | |
| HK1254347B (en) | Therapeutic polymeric nanoparticles and methods of making and using same |